| Origin, fate and dynamics of macrophages at central nervous system interfaces T Goldmann, P Wieghofer, MJC Jordão, F Prutek, N Hagemeyer, ... Nature immunology 17 (7), 797-805, 2016 | 744 | 2016 |
| Acute graft-versus-host disease—biologic process, prevention, and therapy R Zeiser, BR Blazar New England Journal of Medicine 377 (22), 2167-2179, 2017 | 678 | 2017 |
| Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production R Zeiser, VH Nguyen, A Beilhack, M Buess, S Schulz, J Baker, CH Contag, ... Blood 108 (1), 390-399, 2006 | 532 | 2006 |
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, ... Leukemia 29 (10), 2062-2068, 2015 | 492 | 2015 |
| Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R K Wilhelm, J Ganesan, T Müller, C Dürr, M Grimm, A Beilhack, CD Krempl, ... Nature medicine 16 (12), 1434-1438, 2010 | 410 | 2010 |
| Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment G Mikhaylov, U Mikac, AA Magaeva, VI Itin, EP Naiden, I Psakhye, ... Nature nanotechnology 6 (9), 594-602, 2011 | 397 | 2011 |
| Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells R Zeiser, DB Leveson-Gower, EA Zambricki, N Kambham, A Beilhack, ... Blood, The Journal of the American Society of Hematology 111 (1), 453-462, 2008 | 389 | 2008 |
| Pathophysiology of chronic graft-versus-host disease and therapeutic targets R Zeiser, BR Blazar New England Journal of Medicine 377 (26), 2565-2579, 2017 | 374 | 2017 |
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease S Spoerl, NR Mathew, M Bscheider, A Schmitt-Graeff, S Chen, T Mueller, ... Blood, The Journal of the American Society of Hematology 123 (24), 3832-3842, 2014 | 356 | 2014 |
| CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation K Rakhra, P Bachireddy, T Zabuawala, R Zeiser, L Xu, A Kopelman, ... Cancer cell 18 (5), 485-498, 2010 | 331 | 2010 |
| Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease R Zeiser, N von Bubnoff, J Butler, M Mohty, D Niederwieser, R Or, J Szer, ... New England Journal of Medicine 382 (19), 1800-1810, 2020 | 307 | 2020 |
| Immunodominance and functional alterations of tumor‐associated antigen‐specific CD8+ T‐cell responses in hepatocellular carcinoma T Flecken, N Schmidt, S Hild, E Gostick, O Drognitz, R Zeiser, ... Hepatology 59 (4), 1415-1426, 2014 | 279 | 2014 |
| Continuous T cell receptor signals maintain a functional regulatory T cell pool JC Vahl, C Drees, K Heger, S Heink, JC Fischer, J Nedjic, N Ohkura, ... Immunity 41 (5), 722-736, 2014 | 271 | 2014 |
| In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation VH Nguyen, R Zeiser, DL DaSilva, DS Chang, A Beilhack, CH Contag, ... Blood 109 (6), 2649-2656, 2007 | 241 | 2007 |
| Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage L Schwab, L Goroncy, S Palaniyandi, S Gautam, A Triantafyllopoulou, ... Nature medicine 20 (6), 648-654, 2014 | 235 | 2014 |
| Lack of the purinergic receptor P2X7 results in resistance to contact hypersensitivity FC Weber, PR Esser, T Müller, J Ganesan, P Pellegatti, MM Simon, ... Journal of Experimental Medicine 207 (12), 2609-2619, 2010 | 223 | 2010 |
| In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity R Nishimura, J Baker, A Beilhack, R Zeiser, JA Olson, EI Sega, M Karimi, ... Blood, The Journal of the American Society of Hematology 112 (6), 2563-2574, 2008 | 218 | 2008 |
| The Nlrp3 inflammasome regulates acute graft-versus-host disease D Jankovic, J Ganesan, M Bscheider, N Stickel, FC Weber, G Guarda, ... Journal of Experimental Medicine 210 (10), 1899-1910, 2013 | 215 | 2013 |
| Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European … O Penack, M Marchetti, T Ruutu, M Aljurf, A Bacigalupo, F Bonifazi, ... The Lancet Haematology 7 (2), e157-e167, 2020 | 204 | 2020 |
| Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ... Nature medicine 24 (3), 282-291, 2018 | 191 | 2018 |
